Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
InflaRx N.V. most recently reported annual revenue of 0, a net loss of 46.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
InflaRx N.V.: net profit was positive in 0 of 10 reported years; operating margin moved from -70685.6% to -164525.5%, a shift of -93839.9 percentage points; the most recent year shows a net loss of 46.0M.
Income Statement — 10 Years (millions, reporting currency)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
0
0
0
0
0
0
0
0
0
0
Operating Expenses
7.0M
19.0M
38.0M
57.0M
34.0M
48.0M
32.0M
45.0M
53.0M
48.0M
Operating Profit
−7.0M
−19.0M
−38.0M
−57.0M
−34.0M
−48.0M
−32.0M
−45.0M
−53.0M
−48.0M
Operating Margin
—
—
—
—
—
—
—
-70685.6%
-31911.4%
-164525.5%
Other Income
−2.0M
−5.0M
8.0M
4.0M
0
2.0M
3.0M
2.0M
7.0M
3.0M
Interest
2.0M
2.0M
0
0
0
0
0
0
0
0
Depreciation
0
0
0
1.0M
1.0M
1.0M
1.0M
1.0M
0
0
Profit Before Tax
−9.0M
−24.0M
−30.0M
−53.0M
−34.0M
−46.0M
−29.0M
−43.0M
−46.0M
−46.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
-0.0%
-0.0%
Net Profit
−9.0M
−24.0M
−30.0M
−53.0M
−34.0M
−46.0M
−29.0M
−43.0M
−46.0M
−46.0M
EPS
−0.38
−1.03
−1.19
−1.91
−1.26
−1.10
−0.61
−0.78
−0.78
−0.66
Quarterly Results — Last 12 Quarters (millions, reporting currency)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
0
0
0
0
0
0
0
0
0
0
0
0
Operating Expenses
13.0M
13.0M
15.0M
15.0M
10.0M
13.0M
13.0M
10.0M
13.0M
7.0M
7.0M
6.0M
Operating Profit
−13.0M
−12.0M
−15.0M
−15.0M
−10.0M
−13.0M
−13.0M
−9.0M
−13.0M
−7.0M
−7.0M
−6.0M
Operating Margin
-582075.0%
-34655.2%
-242200.1%
-12405.2%
2308149.2%
—
-32524.7%
-39769.2%
37891.1%
—
—
—
Interest
0
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
−16.0M
−10.0M
−13.0M
−17.0M
−5.0M
−8.0M
−14.0M
−12.0M
−11.0M
−6.0M
−11.0M
−2.0M
Tax rate (%)
0.0%
0.0%
0.0%
-0.0%
0.0%
0.0%
0.0%
-0.1%
0.0%
0.0%
0.0%
0.0%
Net Profit
−16.0M
−10.0M
−14.0M
−17.0M
−5.0M
−8.0M
−14.0M
−12.0M
−11.0M
−6.0M
−11.0M
−2.0M
EPS
−0.26
−0.16
−0.24
−0.30
−0.09
−0.13
−0.21
−0.18
−0.14
−0.08
−0.09
−0.02
Over the 10 years reported for InflaRx N.V., borrowings decreased from 53.0M in 2016 to 1.0M in 2025, cash stood at 16.0M in the latest year, shareholders' equity was 9.0M, current assets covered current liabilities 4.15 times.
Balance Sheet — 10 Years (millions, reporting currency)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
30.0M
124.0M
159.0M
122.0M
88.0M
125.0M
102.0M
120.0M
76.0M
55.0M
Current Assets
29.0M
124.0M
158.0M
119.0M
86.0M
96.0M
97.0M
109.0M
72.0M
54.0M
Cash
29.0M
123.0M
55.0M
33.0M
26.0M
26.0M
16.0M
13.0M
18.0M
16.0M
Inventory
0
1.0M
0
0
0
0
0
11.0M
7.0M
0
Receivables
0
0
0
0
0
1.0M
1.0M
0
0
1.0M
Fixed Assets
0
0
1.0M
1.0M
1.0M
2.0M
2.0M
1.0M
1.0M
1.0M
Capital Work in Progress
0
0
0
0
0
0
0
0
0
0
Investments
0
0
101.0M
83.0M
55.0M
84.0M
68.0M
9.0M
3.0M
31.0M
Other Assets
0
0
0
0
0
0
0
0
0
0
Total Liabilities
55.0M
5.0M
8.0M
14.0M
10.0M
20.0M
14.0M
18.0M
15.0M
14.0M
Current Liabilities
2.0M
5.0M
8.0M
14.0M
10.0M
19.0M
13.0M
17.0M
14.0M
13.0M
Borrowings
53.0M
0
0
1.0M
1.0M
1.0M
1.0M
1.0M
1.0M
1.0M
Other Liabilities
2.0M
5.0M
8.0M
14.0M
10.0M
18.0M
13.0M
17.0M
14.0M
13.0M
Equity
0
3.0M
3.0M
3.0M
3.0M
5.0M
5.0M
7.0M
7.0M
9.0M
Reserves
−26.0M
119.0M
151.0M
107.0M
78.0M
105.0M
88.0M
103.0M
61.0M
42.0M
For InflaRx N.V., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at 34.0M; free cash flow was positive in 0 of 10 years.
Cash Flow Statement — 10 Years (millions, reporting currency)
InflaRx N.V. (IFRX) reported annual revenue of 0 in its most recent fiscal year.
What is InflaRx N.V.'s net profit?
InflaRx N.V. (IFRX) reported a net loss of 46.0M in its most recent fiscal year.
What is IFRX EV/EBITDA?
InflaRx N.V.'s enterprise value to EBITDA (EV/EBITDA) ratio is -4.54. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks